Compare · ESTA vs EW
ESTA vs EW
Side-by-side comparison of Establishment Labs Holdings Inc. (ESTA) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESTA and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $49.50B, about 22.6x ESTA ($2.19B).
- Over the past year, ESTA is up 94.3% and EW is up 12.5% - ESTA leads by 81.9 points.
- ESTA has been more active in the news (11 items in the past 4 weeks vs 7 for EW).
- EW has more recent analyst coverage (25 ratings vs 13 for ESTA).
- Company
- Establishment Labs Holdings Inc.
- Edwards Lifesciences Corporation
- Price
- $74.78+0.77%
- $85.84-0.14%
- Market cap
- $2.19B
- $49.50B
- 1M return
- +3.77%
- +3.72%
- 1Y return
- +94.31%
- +12.46%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 11
- 7
- Recent ratings
- 13
- 25
Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ESTA
- See footnote 3 Jw Asset Management, Llc sold $6,636,886 worth of shares (90,533 units at $73.31) (SEC Form 4)
- After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
- Director Schutter Edward J was granted 2,354 shares, increasing direct ownership by 1% to 177,736 units (SEC Form 4)
- Director Slotkin Bryan was granted 2,354 shares, increasing direct ownership by 8% to 32,610 units (SEC Form 4)
- Director Custin Ann was granted 2,354 shares, increasing direct ownership by 11% to 24,086 units (SEC Form 4)
- Director Lewin Nicholas Sheridan was granted 2,354 shares, increasing direct ownership by 0.22% to 1,079,669 units (SEC Form 4)
- Director Gillin Leslie was granted 2,354 shares, increasing direct ownership by 15% to 18,398 units (SEC Form 4)
- Large owner Jw Asset Management, Llc sold $1,466,333 worth of shares (20,579 units at $71.25) (SEC Form 4)
- Establishment Labs Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
Latest EW
- SEC Form 3 filed by new insider Mistras Theodora
- SVP, Corporate Controller Dahl Andrew M. sold $48,853 worth of shares (568 units at $86.08), decreasing direct ownership by 4% to 15,334 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $2,000,193 worth of shares (23,145 units at $86.42) (SEC Form 4)
- SEC Form SD filed by Edwards Lifesciences Corporation
- CVP, TMTT & Surgical Chopra Daveen sold $126,905 worth of shares (1,500 units at $84.60), decreasing direct ownership by 3% to 44,324 units (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 620 shares at a strike of $72.68 and sold $50,307 worth of shares (620 units at $81.14) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $1,472,678 worth of shares (17,968 units at $81.96), decreasing direct ownership by 30% to 22,798 units (SEC Form 4)
- CEO Zovighian Bernard J converted options into 47,207 shares, covered exercise/tax liability with 26,198 shares, gifted 26,640 shares, received a gift of 26,640 shares and sold $2,833,013 worth of shares (36,351 units at $77.93) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 99,165 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr converted options into 13,457 shares and covered exercise/tax liability with 7,469 shares, increasing direct ownership by 22% to 32,766 units (SEC Form 4)
- CVP, TMTT & Surgical Chopra Daveen converted options into 13,583 shares and covered exercise/tax liability with 7,538 shares, increasing direct ownership by 15% to 45,824 units (SEC Form 4)